Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide
Atefeh Khodakarami(Tabriz University of Medical Sciences), Farhad Jadidi‐Niaragh(Tabriz University of Medical Sciences), Rafieh Bagherifar(Tabriz University of Medical Sciences), Hamed Mohammadi(Tehran University of Medical Sciences), Seyyed Sina Hejazian(Tabriz University of Medical Sciences), Sepideh Izadi(German Cancer Research Center), Vahid Karpisheh(Tabriz University of Medical Sciences), Atefeh Nazer(Tabriz University of Medical Sciences), Mahsa Afsari Kashani(Tabriz University of Medical Sciences), Shiva Abolhasani(Tabriz University of Medical Sciences), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Bentolhoda Rashidi(Tabriz University of Medical Sciences), Armin Mahmoudsalehi Kheshti(Tabriz University of Medical Sciences), Ali Masjedi(Tabriz University of Medical Sciences), Abbas Ali Hosseinpour Feizi(Tabriz University of Medical Sciences), Ali Akbar Movassaghpour
Cited by 16
Related Papers
CAR T cells in solid tumors: challenges and opportunities
|Stem Cell Research & Therapy|2021|573
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
The paradox of Th17 cell functions in tumor immunity
|Cellular Immunology|2017|222
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202